|
Name |
Amoritin
|
Molecular Formula | C31H38O6 | |
IUPAC Name* |
5,7-dihydroxy-2-[4-hydroxy-3-methoxy-5-(3-methylbut-2-enyl)phenyl]-6,8-bis(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
|
|
SMILES |
CC(=CCC1=C(C(=CC(=C1)C2CC(=O)C3=C(C(=C(C(=C3O2)CC=C(C)C)O)CC=C(C)C)O)OC)O)C
|
|
InChI |
InChI=1S/C31H38O6/c1-17(2)8-11-20-14-21(15-26(36-7)28(20)33)25-16-24(32)27-30(35)22(12-9-18(3)4)29(34)23(31(27)37-25)13-10-19(5)6/h8-10,14-15,25,33-35H,11-13,16H2,1-7H3
|
|
InChIKey |
LBUIMKICYMGNNI-UHFFFAOYSA-N
|
|
Synonyms |
Amoritin; CHEBI:186437; LMPK12140440; 5,7-dihydroxy-2-[4-hydroxy-3-methoxy-5-(3-methylbut-2-enyl)phenyl]-6,8-bis(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
|
|
CAS | NA | |
PubChem CID | 42608008 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 506.6 | ALogp: | 8.1 |
HBD: | 3 | HBA: | 6 |
Rotatable Bonds: | 8 | Lipinski's rule of five: | Rejected |
Polar Surface Area: | 96.2 | Aromatic Rings: | 3 |
Heavy Atoms: | 37 | QED Weighted: | 0.334 |
Caco-2 Permeability: | -4.815 | MDCK Permeability: | 0.00001270 |
Pgp-inhibitor: | 0.933 | Pgp-substrate: | 0.825 |
Human Intestinal Absorption (HIA): | 0.038 | 20% Bioavailability (F20%): | 0.983 |
30% Bioavailability (F30%): | 0.199 |
Blood-Brain-Barrier Penetration (BBB): | 0.008 | Plasma Protein Binding (PPB): | 82.80% |
Volume Distribution (VD): | 3.989 | Fu: | 17.87% |
CYP1A2-inhibitor: | 0.083 | CYP1A2-substrate: | 0.538 |
CYP2C19-inhibitor: | 0.89 | CYP2C19-substrate: | 0.227 |
CYP2C9-inhibitor: | 0.895 | CYP2C9-substrate: | 0.936 |
CYP2D6-inhibitor: | 0.118 | CYP2D6-substrate: | 0.256 |
CYP3A4-inhibitor: | 0.217 | CYP3A4-substrate: | 0.177 |
Clearance (CL): | 15.533 | Half-life (T1/2): | 0.092 |
hERG Blockers: | 0.026 | Human Hepatotoxicity (H-HT): | 0.944 |
Drug-inuced Liver Injury (DILI): | 0.526 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.663 | Maximum Recommended Daily Dose: | 0.193 |
Skin Sensitization: | 0.944 | Carcinogencity: | 0.041 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.323 |
Respiratory Toxicity: | 0.621 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC005245 | 0.433 | D07MGA | 0.309 | ||||
ENC006119 | 0.378 | D0Q0PR | 0.266 | ||||
ENC004640 | 0.360 | D0WY9N | 0.245 | ||||
ENC004238 | 0.349 | D03VFL | 0.228 | ||||
ENC004153 | 0.336 | D06BLQ | 0.223 | ||||
ENC003768 | 0.331 | D0AZ8C | 0.222 | ||||
ENC002489 | 0.331 | D0I9HF | 0.218 | ||||
ENC004840 | 0.328 | D06GCK | 0.216 | ||||
ENC004838 | 0.326 | D01XWG | 0.216 | ||||
ENC000859 | 0.324 | D04FBR | 0.214 |